UNSPSC 51373455: Codeine/potassium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373455 Codeine/potassium citrate is a Commodity code under which state and local governments procure pharmaceutical products, though recent solicitation activity shows significant mismatch with the code's nominal scope. The two most recent opportunities posted under this code involve naloxone (an opioid antagonist) and a broad generic multi-source pharmaceutical and OTC product framework rather than codeine-potassium citrate combinations specifically. State and local issuing bodies soliciting under the code include county health departments and state-administered cooperative purchasing alliances. Seminole County, Florida issued an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon.

Recent activity spans Florida and Minnesota-led cooperative purchasing serving multiple states. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) required electronic bid submission with fixed-fee pricing and included FEMA compliance requirements. The MMCAP RFP (S1070000015802, due March 26, 2026) is the more recent posting and represents a multi-state cooperative vehicle requiring NDC-specific product information, cGMP and DSCSA compliance certification, relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co.), and pricing models including flat price, net price formats, or WAC-minus structures. Contracts awarded under MMCAP will be effective July 1, 2026, with a two-year term and optional extensions. The code's nominal scope and actual procurement activity diverge substantially; the recent opportunities reflect broad-based pharmaceutical procurement frameworks rather than codeine-specific formulations.